KAND567 Versus Placebo in Subjects Hospitalized With COVID-19 - Trial NCT06012565
Access comprehensive clinical trial information for NCT06012565 through Pure Global AI's free database. This Phase 2 trial is sponsored by Kancera AB and is currently Terminated. The study focuses on Covid19. Target enrollment is 35 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Kancera AB
Timeline & Enrollment
Phase 2
Oct 11, 2020
Aug 07, 2021
Primary Outcome
Safety and tolerability of KAND567, as measured by the occurrence of adverse events (AEs) and serious adverse events (SAEs).
Summary
The study is a phase II, randomized, 2-arm parallel-group, double-blind study to explore the
 efficacy, safety, tolerability and pharmacokinetics of KAND567 versus placebo in COVID-19
 subjects in need of oxygen treatment.
 
 The target was to include forty (40) subjects with diagnosed COVID-19 for participation in
 the study. If at screening all criteria for study participation were fulfilled and informed
 consent signed, the subject was enrolled and randomized into one of the two arms. After
 randomization, the subjects were to receive KAND567 or placebo treatment for 7 days.
 
 After the treatment period the subjects returned to ordinary clinical follow-up, but a study
 follow-up visit was to be planned for Day 21 and 90.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06012565
Non-Device Trial